# Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study

> **NCT07746895** · PHASE4 · RECRUITING · sponsor: **Swedish Orphan Biovitrum** · enrollment: 150 (estimated)

## Conditions studied

- C3 Glomerulopathy (C3G)
- Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

## Interventions

- **DRUG:** Pegcetacoplan

## Key facts

- **NCT ID:** NCT07746895
- **Lead sponsor:** Swedish Orphan Biovitrum
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-05
- **Primary completion:** 2031-12-31
- **Final completion:** 2032-01-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07746895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07746895, "Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07746895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*